703 related articles for article (PubMed ID: 23206211)
1. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
[TBL] [Abstract][Full Text] [Related]
2. Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.
Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson TM; Xie J; Erder MH; Dammerman RS; Robertson B; Wu EQ
Am J Manag Care; 2014 Sep; 20(9):711-21. PubMed ID: 25365746
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.
Lachaine J; De G; Sikirica V; Van Stralen J; Hodgkins P; Yang H; Heroux J; Ben Amor L
Can J Psychiatry; 2014 Nov; 59(11):597-608. PubMed ID: 25565476
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada.
Lachaine J; Ben Amor L; Pringsheim T; Burns J; van Stralen J
J Child Adolesc Psychopharmacol; 2019 Dec; 29(10):730-739. PubMed ID: 31433205
[No Abstract] [Full Text] [Related]
5. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
Sohn M; Talbert J; Moga DC; Blumenschein K
Atten Defic Hyperact Disord; 2016 Sep; 8(3):149-58. PubMed ID: 27143026
[TBL] [Abstract][Full Text] [Related]
6. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
7. Impact of a Step Therapy for Guanfacine Extended-Release on Medication Utilization and Health Care Expenditures Among Individuals Receiving Treatment for ADHD.
Suehs BT; Sikirica V; Mudumby P; Dufour R; Patel NC
J Manag Care Spec Pharm; 2015 Sep; 21(9):793-802, 802a-802i. PubMed ID: 26308226
[TBL] [Abstract][Full Text] [Related]
8. Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder.
Bali V; Kamble PS; Aparasu RR
J Manag Care Spec Pharm; 2015 Jun; 21(6):486-98. PubMed ID: 26011550
[TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
Wade RL; Kindermann SL; Hou Q; Thase ME
J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
Sultan RS; Wang S; Crystal S; Olfson M
JAMA Netw Open; 2019 Jul; 2(7):e197850. PubMed ID: 31348506
[TBL] [Abstract][Full Text] [Related]
11. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.
Olfson M; Marcus SC; Zhang HF; Wan GJ
J Manag Care Pharm; 2007 Sep; 13(7):570-7. PubMed ID: 17874863
[TBL] [Abstract][Full Text] [Related]
12. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
[TBL] [Abstract][Full Text] [Related]
14. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
[TBL] [Abstract][Full Text] [Related]
15. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
[TBL] [Abstract][Full Text] [Related]
16. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
May DE; Kratochvil CJ
Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
[TBL] [Abstract][Full Text] [Related]
17. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Seetasith A; Greene M; Hartry A; Burudpakdee C
J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
[TBL] [Abstract][Full Text] [Related]
18. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
19. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
20. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
Rajagopalan K; Rashid N; Kumar S; Doshi D
J Med Econ; 2023; 26(1):34-42. PubMed ID: 36444507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]